Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:51:58.977Z.
Calculation as of: 2026-10-06T16:51:58.977Z.
Quote observation: 2026-10-06T16:43:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 581b2fbaae035830ca35d06372124b56c7048e0f0ab23ef832a371d1053372ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$13.66M
EV/FCF Ratio
11.03x
TTM Avg
13.15x
3Y Avg
13.15x
5Y Avg
13.15x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.66M | 11.03x | 13.15x | 13.15x | 13.15x |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.79M | N/A | N/A | N/A | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.33M | N/A | N/A | N/A | N/A |
| Sintx Technologies, Inc. (SINT)vs › | $13.92M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.10M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.90M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.88M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.57M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
